Cantor Fitzgerald downgraded GW Pharmaceuticals from Overweight to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl
LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical. Mentioned in today's commentary includes: Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR
15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold
Citigroup downgraded GW Pharmaceuticals from Buy to Neutral
HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)
SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)